drugset / Trial / NCT02809963

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

NCT02809963

Phase 4 Completed 140 enrolled Herlev Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.

Timeline

Start
2015-11
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eplerenone Unknown 100 mg Oral
Comparator Eplerenone Unknown 200 mg Oral